Episode Details

Alnylam Pharmaceuticals is exploding in biotech with six RNAi drugs already on the market and Q1 revenue soaring 121% to over a billion dollars—driven by a rare nerve disease treatment. They’re now targeting massive markets like cardiomyopathy and partnering with Roche on a revolutionary hypertension therapy needing just annual doses. Late-stage trials cover autoimmune and blood disorders, all powered by their defensible RNAi platform and AI-driven innovation. While stock is pricey relative to earnings and faces pricing pressure from rivals like Pfizer, Wall Street sees huge upside—some predicting a 45% surge—thanks to profitability, growth, and a pipeline poised to tackle major health challenges.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/c98f5228eab1df48